Search

Displaying results 7731 - 7740 of 10000 in total
  1. Drug

    Salmon, unspecified

    go.drugbank.com/drugs/DB11014
    Approved

    Salmon, unspecified allergenic extract is used in allergenic testing.

  2. Drug

    Penicillium digitatum

    go.drugbank.com/drugs/DB11023
    Approved

    Penicillium digitatum allergenic extract is used in allergenic testing.

  3. Drug

    AM365

    go.drugbank.com/drugs/DB06564
    Experimental

    Detiviciclovir (AM365) is an antiviral nucleoside analogue.

  4. Drug

    Isoxicam

    go.drugbank.com/drugs/DB08942
    ApprovedWithdrawn

    Isoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.

  5. Drug

    Konjac mannan

    go.drugbank.com/drugs/DB14963
    Investigational

    Konjac mannan is under investigation in clinical trial NCT01709955 (The Effects of Glucomannan on Weight Loss).

  6. Drug

    JTC-801 free base

    go.drugbank.com/drugs/DB17033
    Experimental

    An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.[A253027]

    Synonyms: Benzamide, n-(4-amino-2-methyl-6-quinolinyl)-2-((4-ethylphenoxy)methyl)-
  7. Drug

    Diaminopyrimidine oxide

    go.drugbank.com/drugs/DB18756
    Approved

    Diaminopyrimidine oxide is a compound similar to [minoxidil] which is used to aid in hair growth.

    Synonyms: 2,4-diaminopyrimidine 3-n-oxide
  8. Drug

    Temocillin

    go.drugbank.com/drugs/DB12343
    ApprovedInvestigationalWithdrawn

    Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.

  9. Drug

    Zotarolimus

    go.drugbank.com/drugs/DB18761
    Investigational

    Zotarolimus is an immunosuppressant under investigation for use in drug-eluting stents.

  10. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … [L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients